

Edgar Filing: GALILEO INTERNATIONAL INC - Form SC 13D

GALILEO INTERNATIONAL INC  
Form SC 13D  
June 22, 2001

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13D  
(Rule 13d-101)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO  
RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a)

Galileo International, Inc.

-----  
(Name of Issuer)

Common Stock, Par Value \$0.01 Per Share

-----  
(Title of Class of Securities)

363547100

-----  
(CUSIP Number of Class of Securities)

Eric J. Bock, Esq.  
Senior Vice President, Law and Corporate Secretary  
Cendant Corporation  
9 West 57th Street  
New York, New York 10019  
Telephone: (202) 431-1836

Copy to:  
Patricia Moran, Esq.  
Skadden, Arps, Slate, Meagher & Flom LLP  
One Rodney Square  
Wilmington, Delaware 19801  
(302) 651-3000

-----  
(Name, Address and Telephone Number of Person Authorized  
to Receive Notices and Communications)

June 15, 2001

-----  
(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following: ( )

(Continued on following pages)  
(Page 1 of 14 Pages)

CUSIP No. 363547100

13D

Page 2 of 14 Pages

-----  
(1) NAMES OF REPORTING PERSONS  
S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS  
Cendant Corporation (I.R.S. IDENTIFICATION NO. 06-0918165)

Edgar Filing: GALILEO INTERNATIONAL INC - Form SC 13D

- 
- (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP: (a) ( )  
(b) ( )
- 
- (3) SEC USE ONLY
- 
- (4) SOURCE OF FUNDS  
OO
- 
- (5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED  
PURSUANT TO ITEMS 2(d) or 2(e): ( )
- 
- (6) CITIZENSHIP OR PLACE OF ORGANIZATION  
Delaware
- 
- |                                  |  |
|----------------------------------|--|
| NUMBER OF<br>SHARES              | (7) SOLE VOTING POWER<br>17,041,071(1) (See Items 3, 4 and 5)      |
| BENEFICIALLY<br>OWNED BY<br>EACH | (8) SHARED VOTING POWER<br>15,490,000(2) (See Items 3 and 5)       |
| REPORTING<br>PERSON<br>WITH      | (9) SOLE DISPOSITIVE POWER<br>17,041,071(1) (See Items 3, 4 and 5) |
|                                  | (10) SHARED DISPOSITIVE POWER<br>None                              |
- 
- (11) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING  
PERSON 32,531,071(3) (See Items 3, 4 and 5)
- 
- (12) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 11 EXCLUDES CERTAIN  
SHARES: ( )
- 
- (13) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11  
31.2%(4) (See Items 3, 4 and 5)
- 
- (14) TYPE OF REPORTING PERSON  
CO
- 

1 Represents shares of common stock, par value \$.01 per share ("Galileo Common Stock"), of Galileo International, Inc. ("Galileo") purchasable by Cendant Corporation ("Cendant") upon exercise of an option (the "Option") granted pursuant to the Stock Option Agreement, dated as of June 15, 2001, between Galileo and Cendant (the "Option Agreement") which is described in Items 3, 4 and 5 of this Schedule 13D. Prior to the exercise of the Option, Cendant is not entitled to any rights as a stockholder of Galileo as to the shares covered by the Option and disclaims any beneficial ownership thereof. The Option entitles Cendant to purchase up to 17,041,071 shares (the "Option Shares") representing 19.5% of the issued and outstanding shares of Galileo Common Stock, subject to adjustment in certain customary circumstances. The Option may be exercised by Cendant, in whole or in part, at any time after the Merger Agreement becomes terminable by Cendant (i) under circumstances which could entitle Cendant to the termination fee under the Merger Agreement regardless of whether the Merger Agreement is actually terminated and (ii) the Support Agreement is terminated in accordance with its terms. None of such events has occurred at the time of this

## Edgar Filing: GALILEO INTERNATIONAL INC - Form SC 13D

filing. The number of shares of Galileo Common Stock indicated represents approximately 19.5% of the total outstanding shares of Galileo Common Stock as of May 31, 2001 (as represented by Galileo in the Merger Agreement), excluding shares issuable upon exercise of the Option.

- 2 Cendant has voting power of 15,940,000 shares (the "United Shares") of Galileo Common Stock beneficially owned by United Air Lines, Inc. ("United") pursuant to proxy granted to Cendant under a Transaction Support Agreement (the "Support Agreement"), dated as of June 15, 2001. United may terminate the Support Agreement and revoke its proxy upon the occurrence of certain events (see Items 3 and 5). Cendant is not entitled to any rights as a stockholder of Galileo, has no dispositive power, and expressly disclaims any beneficial ownership of the United Shares.
- 3 As discussed in Items 3, 4, and 5 of this Schedule 13D, Cendant may not exercise the Option and acquire the Option Shares at any time prior to the termination of the Support Agreement. Accordingly, at no time will Cendant have voting and/or beneficial ownership of both the United Shares and the Option Shares and therefore Cendant will never have the power to vote and/or have beneficial ownership of more than 17,041,071 of the outstanding shares of Galileo Common Stock, subject to adjustment in certain customary circumstances.
- 4 As discussed in Note 3 above and in Items 3, 4, and 5 of this Schedule 13D, at no time will Cendant have voting and dispositive power with respect to both the United Shares and the Option Shares. Accordingly, Cendant will never have the power to vote and/or have beneficial ownership of more than 19.5% of the outstanding shares of Galileo Common Stock. The 31.2% of Galileo Common Stock gives effect to the United Shares and the Option Shares and is calculated based on the issuance by Galileo of an additional 17,041,071 shares upon exercise of the Option.

### Item 1. Security and Issuer

This Schedule 13D relates to the common stock, par value \$0.01 per share (the "Galileo Common Stock," an individual share of which is a "Galileo Share"), of Galileo International, Inc., a Delaware corporation ("Galileo"). The principal offices of Galileo are located at 9700 West Higgins Road, Suite 400, Rosemont, Illinois 60018.

### Item 2. Identity and Background

This Schedule 13D is filed by Cendant Corporation, a Delaware corporation ("Cendant"). Cendant is a diversified global provider of business and consumer services primarily within the real estate and travel sectors. The Company's fee-for-service businesses include hotel, real estate and tax preparation franchising; rental cars, fleet leasing and fuel cards; mortgage origination and employee relocation; customer loyalty programs; vacation exchange and rental services and vacation interval sales. Other business units include the UK's largest private car park operator and electronic reservations processing for the travel industry. With headquarters in New York City, the Company has approximately 60,000 employees and operates in over 100 countries. Cendant's principal executive offices are located at 9 West 57th Street, New York, New York 10019.

The name, business address, present principal occupation and citizenship of each executive officer and director is set forth in

## Edgar Filing: GALILEO INTERNATIONAL INC - Form SC 13D

Schedule A to this Schedule 13D and is specifically incorporated herein by reference.

On June 14, 2000, the Securities and Exchange Commission (the "SEC") instituted and simultaneously settled an administrative proceeding, Administrative Proceeding File No. 3-10225, against Cendant in connection with certain accounting irregularities at the former CUC International, Inc., which merged with HFS Incorporated in December 1997 to form Cendant. The SEC found that, as a result of such accounting irregularities, Cendant violated the periodic reporting, corporate record-keeping and internal controls provisions of the federal securities laws. Without admitting or denying the findings contained in the SEC's administrative order, Cendant consented to the issuance of an SEC order directing Cendant to cease and desist from committing or causing any violation, and any future violation, of the periodic reporting, corporate record-keeping and internal controls provisions of the federal securities laws.

Except as set forth in response to this Item 2, during the last five years, neither Cendant nor, to the best of Cendant's knowledge, any of the individuals referred to in Schedule A, has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction resulting in a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws, or finding violations with respect to such laws.

### Item 3. Source and Amount of Funds or Other Consideration

Cendant, Galileo and Galaxy Acquisition Corp., a Delaware corporation and a subsidiary of Cendant ("Merger Sub"), entered in to an Agreement and Plan of Merger dated as of June 15, 2001 (the "Merger Agreement"). Pursuant to the Merger Agreement, Merger Sub will merge with and into Galileo (the "Merger"), with Galileo continuing as the surviving corporation. Following the Merger, Galileo will be a wholly owned subsidiary of Cendant.

Under the terms of the Merger Agreement, Galileo stockholders will receive a combination of common stock, par value \$.01 per share ("Cendant Common Stock") and cash with an expected value of \$33 per Galileo Share. Galileo stockholders will receive 80.5 percent or more of the purchase price through a tax-free exchange of Cendant Common Stock with a market value of \$26.565 per Galileo share, subject to a collar. The number of shares of Cendant Common Stock will fluctuate within a collar of \$17 to \$20 from 1.563 share of Cendant Common Stock per Galileo Share if the average price of Cendant Common Stock is \$17 per share of Cendant Common Stock during the Pricing Period (as defined in the Merger Agreement) to 1.328 share of Cendant Common Stock per Galileo Share if the average price per share of Cendant Common Stock is \$20 during the Pricing Period. The total number of shares of Cendant Common Stock to be issued will be between 116 million and 137 million shares. If the average price per share of Cendant Common Stock during the Pricing Period is below or above the collar, the value of the transaction will be greater or less than \$33 per Galileo Share since the exchange ratios, as noted above, are fixed for stock consideration outside the collar. If the average price per share of Cendant Common Stock is at or below \$14 during the Pricing Period, Galileo will have a right to terminate the transaction.

The remainder of the purchase price, up to \$6.435 per Galileo share or approximately \$562 million in the aggregate, will be paid in cash. The cash portion of the consideration is limited to 19.5 percent

## Edgar Filing: GALILEO INTERNATIONAL INC - Form SC 13D

of the value of the total consideration on the closing date to be paid to Galileo stockholders.

The Merger is subject to customary closing conditions, including the approval and adoption of the Merger Agreement by Galileo's stockholders, the expiration of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, the receipt of approvals from the European Commission, the Treasurer of the Commonwealth of Australia and the Canadian Commission of Competition, and the satisfaction or waiver of certain other conditions as more fully described in the Merger Agreement.

As an inducement to Cendant entering into the Merger Agreement, Cendant entered into a Transaction Support Agreement (the "Support Agreement"), dated as of June 15, 2001, with United Air Lines, Inc. ("UAL") and Covia LLC, a wholly owned subsidiary of UAL ("Covia", and together with UAL, "United"). The total number of shares of Galileo Common Stock owned of record and/or beneficially by United is 15,940,000 shares (the "United Shares"). Pursuant to the Support Agreement, Covia irrevocably and unconditionally agreed to vote or cause to be voted (including by written consent, if applicable) all of the United Shares (i) in favor of the adoption of the Merger Agreement, (ii) against any Third-Party Acquisition (as defined in the Merger Agreement) and (iii) against any proposed action by Galileo, Galileo's stockholders or any other person the result of which action could prevent or materially delay completion of the Merger.

United agreed not to solicit or participate in any solicitation of proxies with respect to any shares of Galileo Common Stock. United also agreed not to (i) encourage, invite, initiate or solicit any inquiries relating to or the submission or making of a proposal by any person with respect to a Third-Party Acquisition or (ii) participate in or encourage, invite, initiate or solicit negotiations or discussions with, or furnish or cause to be furnished any information to, any person relating to a Third-Party Acquisition; provided, however, that, prior to Galileo's stockholders meeting, if (x) United or Galileo receives an unsolicited bona fide written proposal from any person with respect to a Third-Party Acquisition which United determines in good faith could reasonably be expected to result in a Superior Proposal (as defined in the Merger Agreement), or (y) there is a Superior Proposal which has been made by any person, then United may furnish information to such person and may participate in discussions and negotiations with such person.

United may terminate the Support Agreement and revoke its proxy if Galileo's Board of Directors withdraws its recommendation of the Merger Agreement in favor of a Superior Proposal or if the Merger Agreement is amended and United determines that the amendment is adverse in a material respect to it.

As a further inducement to Cendant entering into the Merger Agreement, Galileo entered into a Stock Option Agreement (the "Option Agreement"), dated as of June 15, 2001, with Cendant. The Option Agreement grants to Cendant an irrevocable option (the "Option") to purchase up to 17,041,071 shares of Galileo Common Stock (the "Option Shares"), subject to customary adjustments, together with the rights associated with such Option Shares issued pursuant to the Rights Agreement (as defined in the Option Agreement) at a purchase price of \$33.00 per Galileo Share. In no event will the number of shares of Galileo Common Stock for which the Option is exercisable exceed 19.5% of the total number of shares of Galileo Common Stock issued and outstanding. The Option may be exercised by Cendant, in whole or in part, at any time after the Merger Agreement becomes terminable by Cendant (i) under circumstances which could

## Edgar Filing: GALILEO INTERNATIONAL INC - Form SC 13D

entitle Cendant to the termination fee under the Merger Agreement regardless of whether the Merger Agreement is actually terminated and (ii) the Support Agreement is terminated in accordance with its terms. None of such events has occurred at the time of this filing. If Cendant proposes to exercise the Option following the record date of Galileo's stockholders meeting, Galileo must take all actions necessary to fix a new record date and to hold its stockholders meeting when Cendant has the opportunity to vote the Option Shares at the stockholders meeting. Galileo's Board of Directors is not, however, required to fix a new record date if it determines in good faith that taking such action would create a substantial probability of violating its fiduciary duties. If the Merger is consummated in accordance with the terms of the Merger Agreement, the Option will not be exercised. No monetary consideration was paid by Cendant to Galileo for the Option.

At any time during which the Option is exercisable, Cendant shall have the right to sell to Galileo and Galileo shall have the obligation to repurchase from Cendant (the "Put") all or any portion of the Option at a price equal to the product obtained by multiplying (i) the difference between (A) the Market/Offer Price (as defined below) for shares of Galileo Common Stock as of the date the notice (the "Notice Date") of the exercises of the Put is given to Galileo and (B) \$33.00, by (ii) the number of Option Shares purchasable pursuant to the Option. If the Put becomes exercisable, and all or any portion of the Option has already been exercised, Galileo would be obligated to repurchase all or any portion of the shares of Galileo Common Stock issued at a price equal to the product obtained by multiplying (i) the higher of (A) \$33.00 and (B) the Market/Offer Price by (ii) the number of Galileo Shares with respect to which Cendant is exercising the Put.

The Market/Offer Price is defined as the higher of (i) the highest price per share offered as of the Notice Date pursuant to any tender or exchange offer or proposed pursuant to any other Third-Party Acquisition proposal which was commenced or proposed prior to the Notice Date and not terminated or withdrawn as of the Notice Date and (ii) the average of the closing sales prices of Galileo Common Stock reported on the NYSE Composite Tape for the 5 consecutive trading days ending on (and including) the trading day immediately preceding the Notice Date.

The Option Agreement also grants Cendant certain registration rights with respect to the Option Shares. Notwithstanding Cendant's right to exercise the Option and the Put, if the Total Payment (as defined in the Option Agreement, which includes any amounts received as a termination fee under the Merger Agreement) received by Cendant exceeds \$100 million, then Cendant may, at its option: (i) reduce the number of shares subject to the Option; (ii) deliver to Galileo for cancellation the previously purchased Option Shares; (iii) pay cash to Galileo; or (iv) any combination thereof.

If Cendant elects to exercise the Option, it currently anticipates that the funds needed to purchase Galileo Shares will be generated by a combination of available working capital and other available borrowing sources.

References to, and descriptions of, the Merger Agreement, the Support Agreement and the Option Agreement as set forth above in this Item 3 are qualified in their entirety by reference to the copies of the Merger Agreement, the Support Agreement and the Option Agreement which are Exhibits 1, 2 and 3, respectively, to this Schedule 13D, and are incorporated in this Item 3 in their entirety where such references and descriptions appear.

## Edgar Filing: GALILEO INTERNATIONAL INC - Form SC 13D

### Item 4. Purpose of Transaction

As stated above, the Support Agreement and the Option Agreement were entered into as an inducement to Cendant entering into the Merger Agreement.

The directors of Merger Sub immediately prior to the effective time of the Merger will become the directors of the Galileo upon consummation of the Merger in accordance with the terms of the Merger Agreement.

Cendant anticipates that if the Merger is completed, Galileo will become a wholly owned subsidiary of Cendant and that Cendant will seek to cause the Galileo Common Stock to be delisted from trading on the New York Stock Exchange and to cause the termination of registration of the Galileo Common Stock pursuant to the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended.

Upon completion of the Merger, the Board of Directors of Merger Sub will become the Board of Directors of Galileo. In addition, the Certificate of Incorporation of Galileo will be amended and restated in the Merger and the By-laws of Merger Sub will be the By-laws of Galileo after the consummation of the Merger. The Merger Agreement also requires that Galileo suspend payment of its regular quarterly cash dividend.

Other than as described above in Item 3 and in this Item 4, Cendant has no plans or proposals which relate to, or may result in, any of the matters listed in Items 4(a)-(j) of Schedule 13D (although Cendant reserves the right to develop such plans).

References to, and descriptions of, the Merger Agreement, the Support Agreement and the Option Agreement as set forth above in this Item 4 are qualified in their entirety by reference to the copies of the Merger Agreement, the Support Agreement and the Option Agreement which are Exhibits 1, 2 and 3, respectively, to this Schedule 13D, and are incorporated in this Item 4 in their entirety where such references and descriptions appear.

### Item 5. Interest in Securities of the Issuer

As a result of the Support Agreement, Cendant may be deemed to have the shared power to vote or the right to direct the vote of 15,490,000 shares of Galileo Common Stock owned by United, which constitute approximately 18.2% of the issued and outstanding shares of Galileo Common Stock based on the number of shares of Galileo Common Stock outstanding as of May 31, 2001, as represented by Galileo in the Merger Agreement. Cendant is not, however, entitled to any rights as a stockholder of Galileo, has no dispositive power and expressly disclaims any beneficial ownership of the United Shares.

As a result of the issuance of the Option, Cendant may be deemed to be the beneficial owner of 17,041,071 shares of Galileo Common Stock, which would represent approximately 19.5% of the issued and outstanding shares of Galileo Common Stock based on the number of shares of Galileo Common Stock outstanding as of May 31, 2001, as represented by Galileo in the Merger Agreement. Until the Option is exercised, Cendant does not have any right to vote (or direct the vote of) or dispose (or to direct the disposition of) any shares of Galileo Common Stock that may be purchased upon exercise of the Option. Upon purchase of the Option Shares, Cendant will have sole voting and dispositive power with respect to the Option Shares. As noted in Item 4 above, however, the Option is not currently exercisable and Cendant may not exercise the Option until after

## Edgar Filing: GALILEO INTERNATIONAL INC - Form SC 13D

the Support Agreement is terminated.

At no time shall Cendant have voting and dispositive power with respect to both the United Shares and the Option Shares. Accordingly, Cendant may never have the power to vote and/or have beneficial ownership of more than 19.5% of the outstanding shares of Galileo Common Stock.

Other than as set forth in this Schedule 13D, as of the date hereof (i) neither Cendant nor any subsidiary of Cendant nor, to the best of Cendant's knowledge, any of Cendant's executive officers or directors beneficially owns any shares of Galileo Common Stock and (ii) there have been no transactions in shares of Galileo Common Stock effected during the past 60 days by Cendant or by any subsidiary of Cendant or, to the best of Cendant's knowledge, by any of Cendant's executive officers or directors.

No other person is known by Cendant to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Galileo Common Stock obtainable by Cendant upon exercise of the Option.

Reference to, and descriptions of, the Merger Agreement, Support Agreement and the Option Agreement as set forth in this Item 5 are qualified in their entirety by reference to the copies of the Merger Agreement, the Support Agreement and the Option Agreement listed as Exhibits 1, 2 and 3, respectively, to this Schedule 13D, and incorporated in this Item 5 in their entirety where such references and descriptions appear.

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

The information set forth, or incorporated by reference, in Items 3 through 5 is hereby incorporated by reference.

Copies of the Merger Agreement, the Support Agreement and the Option Agreement are incorporated by reference as Exhibits 1, 2 and 3, respectively, to this Schedule 13D. To the best of Cendant's knowledge, except as described in this Schedule 13D, there are at present no other contracts, arrangements, understandings or relationships among the persons named in Item 2 above, and between any such persons and any person, with respect to any securities of Galileo.

Item 7. Materials to be Filed as Exhibits

Exhibit	Description
1	Agreement and Plan of Merger, dated as of June 15, 2001, among Galileo International, Inc., Cendant Corporation and Galaxy Acquisition Corp. (incorporated by reference to Exhibit 2.1 of Cendant Corporation's Current Report on Form 8-K filed June 18, 2001 (the "Cendant Form 8-K"))
2	Transaction Support Agreement, dated as of June 15, 2001, between Cendant Corporation, United Air Lines, Inc. and Covia LLC (incorporated by reference to Exhibit 99.1 of the Cendant Form 8-K).



Edgar Filing: GALILEO INTERNATIONAL INC - Form SC 13D

3 Stock Option Agreement, dated as of June 15, 2001, between Galileo International, Inc. and Cendant Corporation (incorporated by reference to Exhibit 99.2 of the Cendant Form 8-K).

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Schedule 13D is true, complete and accurate.

June 22, 2001

CENDANT CORPORATION

By: /s/ Eric J. Bock

-----  
Name: Eric J. Bock  
Title: Senior Vice President, Law  
and Corporate Secretary

Schedule A

The name, business address and principal occupation of each executive officer and director of Cendant Corporation are set forth below. Unless otherwise indicated, each occupation set forth opposite an executive officer's name refers to employment with Cendant Corporation. Each of these persons is a United States citizen.

DIRECTORS  
(INCLUDING DIRECTORS WHO ARE EXECUTIVE OFFICERS)

Name	Principal Occupation	Address
Henry R. Silverman	President, Chairman and Chief Executive Officer	Cendant Corporation 9 West 57th Street New York, NY 10019
James E. Buckman	Vice Chairman and General Counsel	Cendant Corporation 9 West 57th Street New York, NY 10019
Stephen P. Holmes	Vice Chairman; Chairman and Chief Executive Officer, Cendant Travel Division	Cendant Corporation 6 Sylvan Way Parsippany, NJ 07054
Martin Edelman	Of Counsel, Paul Hastings Janofsky & Walker	Paul, Hastings, Janofsky & Walker LLP 399 Park Avenue New York, NY 10022
Myra J. Biblowit	President, The Breast Cancer Research Foundation	The Breast Cancer Research Foundation Suite 1209 654 Madison Avenue New York, NY 10021

Edgar Filing: GALILEO INTERNATIONAL INC - Form SC 13D

The Rt. Hon. Brian Mulroney, P.C., LL.D.	Senior Partner, Ogilvy Renault	Ogilvy Renault 1981 McGill College Ave. Suite 1100 Montreal, Quebec H3A 3C1
Robert W. Pittman	President and Co-Chief Operating Officer, AOL Time Warner, Inc.	AOL Time Warner, Inc., 22000 AOL Way Dulles, VA 20166
Sheli Z. Rosenberg	Vice Chairwoman, Equity Group Investments, Inc.	Equity Group Investments, Inc. 2 N. Riverside Plaza Suite 600 Chicago, IL 60606
Leonard S. Coleman	Senior Advisor, Major League Baseball	Cendant Corporation 9 West 57th Street New York, 10019
John C. Malone, Ph.D.	Chairman, Liberty Media Corporation	Liberty Media Corporation 9197 South Ploria St. Englewood, CO 80112
Robert E. Nederlander	President, Nederlander Organization, Inc.	Nederlander Organization, Inc. 1450 Broadway 20th Floor New York, NY 10018
Cheryl D. Mills	Senior Vice President, Corporate Policy and Public Programing, Oxygen Media, Inc.	Oxygen Media, Inc. 75 Ninth Avenue New York, NY 10011
Robert F. Smith	Senior Managing Director, Car Component Technologies, Inc.	Car Component Technologies, Inc. 10 Ironhorse Drive Bedford, NH 03110
Secretary William S. Cohen	Chairman and Chief Executive Officer, The Cohen Group	The Cohen Group 600 13th St. NW Suite 640 Washington, DC 20005

EXECUTIVE OFFICERS WHO ARE NOT DIRECTORS

Name	Principal Occupation	Address
Kevin M. Sheehan	Senior Executive Vice President and Chief Financial Officer	Cendant Corporation 6 Sylvan Way Parsippany, NJ 07054
Richard A. Smith	Chairman and Chief Executive Officer, Real Estate Division	Cendant Corporation 6 Sylvan Way Parsippany, NJ 07054
John W. Chidsey	Chairman and Chief Executive Officer, Diversified Services Division	Cendant Corporation 6 Sylvan Way Parsippany, NJ 07054
Samuel L. Katz	Chief Strategic Officer and	Cendant Corporation

Edgar Filing: GALILEO INTERNATIONAL INC - Form SC 13D

	Senior Executive Vice President, Strategic and Business Development	9 West 57th Street New York NY 10019
Thomas D. Christopoul	Senior Executive Vice President and Chief Administrative Officer	Cendant Corporation 6 Sylvan Way Parsippany, NJ 07054
Toby Ippolito	Executive Vice President and Chief Accounting Officer	Cendant Corporation 6 Sylvan Way Parsippany, NJ 07054